{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:55:11Z","timestamp":1793228111175,"version":"4.5.0"},"reference-count":11,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Subcutaneous (SC) formulations of monoclonal antibodies are rapidly transforming the delivery of cancer immunotherapy. Designed to replace or complement intravenous (IV) administration, SC delivery reduces infusion chair time, improves convenience, and may enhance patient and provider satisfaction while preserving pharmacokinetics (PKs), efficacy, and safety. Recent phase III studies of immune checkpoint inhibitors and bispecific antibodies\u2014including atezolizumab, nivolumab, pembrolizumab, and amivantamab\u2014have consistently demonstrated PK noninferiority and comparable clinical outcomes with IV formulations. Safety profiles are largely unchanged, with immune-related adverse events occurring at similar rates, although mild injection site reactions are more common. Importantly, SC amivantamab has shown a marked reduction in infusion-related reactions relative to IV dosing. Operational studies confirm that SC administration shortens treatment delivery from 30 to 60 minutes to &lt;10 minutes, reduces chair occupancy, and optimizes infusion center capacity. Patient preference studies indicate strong favorability toward SC treatment, with most patients citing convenience, reduced venipunctures, and shorter visits as major advantages. Regulatory approvals now include SC atezolizumab and nivolumab across broad indications, SC amivantamab in Europe, and SC pembrolizumab following positive phase III results. The integration of SC immunotherapy into routine practice may improve patient experience, alleviate pressure on oncology services, and reduce health system costs without compromising outcomes. Future research should focus on implementation, real-world cost-effectiveness, and the potential for SC combinations in multiagent regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-00955","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:59:06Z","timestamp":1767992346000},"page":"968-977","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":7,"title":["Subcutaneous Immunotherapy in Cancer: Where We Are Now, What It Changes, and What to Watch Next"],"prefix":"10.1200","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-4486","authenticated-orcid":true,"given":"Fausto","family":"Petrelli","sequence":"first","affiliation":[{"name":"Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Iaculli","sequence":"additional","affiliation":[{"name":"Oncology Unit, ASST Bergamo Est, Seriate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1374-1831","authenticated-orcid":true,"given":"Alberto","family":"Zambelli","sequence":"additional","affiliation":[{"name":"Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghidini","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2273-0229","authenticated-orcid":true,"given":"Lorenzo","family":"Dottorini","sequence":"additional","affiliation":[{"name":"Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tomasello","sequence":"additional","affiliation":[{"name":"Oncology Unit, ASST Crema, Crema, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw685"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.009"},{"key":"e_1_3_5_4_2","first-page":"100815","article-title":"Primary results from IMscin002: A study to evaluate patient preferences and perceptions of health care professionals for atezolizumab subcutaneous versus intravenous for the treatment of NSCLC","volume":"6","author":"Cappuzzo F","year":"2025","unstructured":"Cappuzzo F, Zvirbule Z, Korbenfeld E, et al: Primary results from IMscin002: A study to evaluate patient preferences and perceptions of health care professionals for atezolizumab subcutaneous versus intravenous for the treatment of NSCLC. JTO Clin Res Rep 6:100815, 2025","journal-title":"JTO Clin Res Rep"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.09.002"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2021.1981286"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.03.012"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01001"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.07.062"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102974"},{"key":"e_1_3_5_11_2","volume-title":"A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1)A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1)","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1)A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1). https:\/\/clinicaltrials.gov\/study\/NCT04870112"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12551-025-01346-2"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:00:22Z","timestamp":1781647222000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/OP-25-00955"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00955","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}